Actual value and historical data chart for Philippines Diabetes Prevalence Percent Of Population Ages 20 To 79

Philippines PH: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 7.070 % in 2017. Philippines PH: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 7.070 % from Dec 2017 (Median) to 2017, with 1 observations. Philippines PH: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Philippines – Table PH.World Bank.WDI: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Philippines PH: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 26.800 % in 2016. This records a decrease from the previous number of 26.900 % for 2015. Philippines PH: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 26.900 % from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 28.400 % in 2005 and a record low of 26.800 % in 2016. Philippines PH: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Philippines – Table PH.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

The Philippines diabetes testing market, specifically focusing on trister test strips, presents a compelling growth opportunity. While precise figures for the trister test strip segment within the broader ₱77.63 million (assuming this is in Philippine Pesos) blood glucose monitoring market are unavailable, we can project its trajectory based on established market trends. Considering the high prevalence of diabetes in the Philippines and increasing awareness of self-management, the demand for trister test strips (a component of self-monitoring blood glucose devices) is likely substantial and growing. The 7.20% CAGR across the entire blood glucose monitoring market suggests a healthy expansion for all related segments, including trister test strips. Drivers include rising diabetes incidence, an aging population requiring more frequent testing, and increasing affordability of home-testing devices. Furthermore, the growing adoption of continuous glucose monitoring (CGM) systems might indirectly impact trister test strip usage, but the substantial number of individuals relying on self-monitoring blood glucose (SMBG) devices will likely ensure continued demand. Potential restraints could include limited healthcare access in certain regions, inconsistent insurance coverage for diabetes supplies, and the emergence of alternative testing technologies. However, the overall outlook remains positive, driven by the increasing need for effective diabetes management within the Philippine population. Further market segmentation within trister test strips themselves could reveal significant insights. For instance, analyzing the market based on the type of glucometer devices compatible with specific test strips, or differentiating between premium and budget options, could yield more granular understandings of market segments and their respective growth rates. Competitive analysis across key players like Becton Dickinson, Medtronic, and Abbott, each with various offerings within the trister test strip market, would also enhance our understanding of the competitive landscape. This segment-specific market analysis will require additional research to yield precise, quantifiable data. However, the existing data points towards a significant and expanding market within the Philippines. Recent developments include: March 2024: Novo Nordisk Philippines collaborated with Roche Diabetes Care and Humanity and Inclusion to launch the Changing Diabetes in Children (CDiC) program in Valenzuela City, Philippines. This five-year program aims to provide comprehensive patient education, bolster the healthcare workforce, establish a network of clinic facilities, and ensure free access to insulin and medical supplies for children and young adults with type 1 diabetes., September 2023: The Department of Health (DOH) cautioned people in the Philippines regarding misleading information about diabetes remedies as a part of the diabetes awareness program. The Department of Health (DOH) stressed that adopting a healthy lifestyle was key to preventing non-communicable diseases, such as diabetes, rather than depending on products sold online.. Key drivers for this market are: Rising Diabetes Prevalence in the Country, Growing Government Initiatives to Boost Adoption of Diabetes Care Devices. Potential restraints include: Rising Diabetes Prevalence in the Country, Growing Government Initiatives to Boost Adoption of Diabetes Care Devices. Notable trends are: The Increasing Diabetes Population in the Philippines is Expected to Drive the Market During the Forecast Period.

Philippines PH: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data was reported at 32.800 NA in 2016. This records a decrease from the previous number of 32.900 NA for 2015. Philippines PH: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data is updated yearly, averaging 32.900 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 34.400 NA in 2005 and a record low of 31.600 NA in 2000. Philippines PH: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Philippines – Table PH.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

The Philippines diabetes care drugs market, while lacking precise figures in the provided data, presents a significant growth opportunity. Considering the global market size of $264.24 billion in 2025 (assuming the "Million" unit refers to USD and the value represents the global market) and a 3.90% CAGR, we can extrapolate potential market dynamics for the Philippines. The prevalence of diabetes in the Philippines, coupled with an aging population and rising urbanization contributing to sedentary lifestyles and poor dietary habits, suggests substantial untapped potential. While specific market segmentation data for the Philippines is absent, we can reasonably assume a market structure mirroring global trends, with a strong demand for oral anti-diabetic drugs (metformin, SGLT-2 inhibitors, DPP-4 inhibitors) and insulin products. The presence of major pharmaceutical companies like Novo Nordisk, Sanofi, and Eli Lilly in the global market suggests their likely involvement in the Philippine market, indicating a competitive landscape dominated by established players. Growth will likely be driven by increasing awareness of diabetes management, improved healthcare infrastructure, and the introduction of newer, more effective drugs. However, challenges such as affordability and accessibility of medication, particularly in rural areas, might act as significant restraints on market growth. Further research specific to the Philippines is needed to provide more precise market sizing and segmentation. The market is expected to expand considerably over the coming years, fueled by these factors. The Philippine diabetes care drugs market is projected to experience significant growth driven by factors such as rising diabetes prevalence, an aging population, and increasing healthcare expenditure. Although precise figures for the Philippine market are unavailable, extrapolation based on global trends and the CAGR of 3.90% indicates a substantial market size. The market is likely segmented similarly to the global market, with a strong demand for oral anti-diabetic medications like Metformin and newer classes of drugs. The market will likely witness intense competition amongst major global players, with factors like pricing, accessibility, and the introduction of innovative treatment options influencing growth. Challenges regarding affordability and accessibility in certain regions might necessitate targeted interventions to maximize market penetration and ensure equitable access to essential medications. Recent developments include: March 2023: The approval of brolucizumab by the Philippine Food and Drug Administration (FDA) for the treatment of visual impairment caused by diabetic macular edema (DME) is a major achievement. DME is a prevalent microvascular complication in diabetic patients that can severely affect their vision and potentially result in blindness. This milestone is particularly significant for working-age individuals with DME, as they often face challenges in adhering to treatment due to the management of various diabetes-related conditions., November 2022: The Centers for Disease Control and Prevention (CDC) established an office in the Philippines in 2022 to strengthen and expand existing partnerships with the Philippines Department of Health (DOH). CDC supports the DOH to advance a broad range of health priorities, including increased global health security in Asia., May 2022: Tirzepatide (Mounjaro) is approved for the treatment of Type 2 diabetes in adults. Tirzepatide's FDA approval marks the first in a new class of diabetes medications: a dual GIP/GLP-1 receptor agonist.. Notable trends are: Oral-Anti Diabetes Drugs is having the highest market share in Current Year.

The Philippines diabetes care devices market was valued at USD 77.69 Million in 2024 and is expected to grow at a CAGR of 7.12%, reaching USD 154.55 Million by 2034. The market growth is driven by increasing prevalence of diabetes and rising adoption of home monitoring devices.

Actual value and historical data chart for Philippines Mortality From Cvd Cancer Diabetes Or Crd Between Exact Ages 30 And 70 Percent

ObjectiveDiabetes is a risk factor for TB mortality and relapse. The Philippines has a high TB incidence with co-morbid diabetes. This study assessed the pre- and post-TB diagnosis costs incurred by people with TB and diabetes (TB-DM) and their households in the Philippines.MethodsLongitudinal data was collected for costs, income, and coping mechanisms of TB-affected households in Negros Occidental and Cebu, the Philippines. Data collection was conducted four times during TB treatment. The data collection tools were developed by adapting WHO’s cross-sectional questionnaire in the Tuberculosis Patient Cost Surveys: A Handbook into a longitudinal study design. Demographic and clinical characteristics, self-reported household income, number of facility visits, patient costs, the proportion of TB-affected households facing catastrophic costs due to TB (>20% of annual household income before TB), coping mechanisms, and social support received were compared by diabetes status at the time of TB diagnosis.Results530 people with TB were enrolled in this study, and 144 (27.2%) had TB-DM based on diabetes testing at the time of TB diagnosis. 75.4% of people with TB-DM were more than 45 years old compared to 50.3% of people with TB-only (p

Philippines PH: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 21.000 NA in 2016. This records a decrease from the previous number of 21.100 NA for 2015. Philippines PH: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 21.800 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 22.700 NA in 2005 and a record low of 21.000 NA in 2016. Philippines PH: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Philippines – Table PH.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Preliminary figures for 2024 indicated that ischaemic heart disease was the leading cause of death in the Philippines. The number of people who died from this illness was estimated at 129.000. Following this, cancer resulted in the deaths of about 74,000 people. Eating habits Heart diseases have been linked to high meat consumption, among others. In the Philippines, pork has been the most consumed meat type, followed closely by chicken. While pork meat is typically produced domestically, the country also imports pork to supplement its supply. However, plant-based food has started gaining popularity among Filipinos. In fact, a 2024 survey revealed that 69 percent of surveyed Filipinos consumed plant-based products, including meat alternatives. Common diseases in the Philippines Aside from heart and cerebrovascular diseases, the Filipino population is also exposed to infections, diabetes, skin diseases, and illnesses resulting from high meat consumption. In 2020, over 700,000 Filipinos contracted acute respiratory tract infections, followed by over 400,000 diagnosed with hypertension. In areas with high exposure to rain, dengue infections and leptospirosis have also become prevalent.

Detail of costs incurred per TB-DM affected households (mean, percentage, 95%CI), by diabetes management status at the time of TB diagnosis.

Full dataset available with associated meta-data for a cross-sectional study in consenting adult Filipino persons registered for tuberculosis treatment at national TB treatment clinics under the TB-DOTS programme. The study protocol is available at: Malnutrition and diabetes in tuberculosis treatment programs in the Philippines ISRCTN12506117Publications using this dataset are listed

In Philippines Human Recombinant Insulin Market, The increasing prevalence of diabetes, advancements in insulin formulations, and expanding healthcare access are the key factors driving this market's growth.

The Philippines oral anti-diabetic drug market was valued at USD 201.81 Million in 2024 and is expected to grow at a CAGR of 4.20%, reaching USD 304.52 Million by 2034. The market growth is driven by rising prevalence of diabetes and increasing accessibility of oral therapies in the Philippines.

Philippines PH: Prevalence of Overweight: Weight for Height: Male: % of Children Under 5 data was reported at 5.400 % in 2013. This records an increase from the previous number of 4.700 % for 2011. Philippines PH: Prevalence of Overweight: Weight for Height: Male: % of Children Under 5 data is updated yearly, averaging 4.150 % from Dec 2003 (Median) to 2013, with 4 observations. The data reached an all-time high of 5.400 % in 2013 and a record low of 2.700 % in 2003. Philippines PH: Prevalence of Overweight: Weight for Height: Male: % of Children Under 5 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Philippines – Table PH.World Bank.WDI: Health Statistics. Prevalence of overweight, male, is the percentage of boys under age 5 whose weight for height is more than two standard deviations above the median for the international reference population of the corresponding age as established by the WHO's new child growth standards released in 2006.; ; World Health Organization, Global Database on Child Growth and Malnutrition. Country-level data are unadjusted data from national surveys, and thus may not be comparable across countries.; Linear mixed-effect model estimates; Estimates of overweight children are also from national survey data. Once considered only a high-income economy problem, overweight children have become a growing concern in developing countries. Research shows an association between childhood obesity and a high prevalence of diabetes, respiratory disease, high blood pressure, and psychosocial and orthopedic disorders (de Onis and Blössner 2003). Childhood obesity is associated with a higher chance of obesity, premature death, and disability in adulthood. In addition to increased future risks, obese children experience breathing difficulties and increased risk of fractures, hypertension, early markers of cardiovascular disease, insulin resistance, and psychological effects. Children in low- and middle-income countries are more vulnerable to inadequate nutrition before birth and in infancy and early childhood. Many of these children are exposed to high-fat, high-sugar, high-salt, calorie-dense, micronutrient-poor foods, which tend be lower in cost than more nutritious foods. These dietary patterns, in conjunction with low levels of physical activity, result in sharp increases in childhood obesity, while under-nutrition continues

According to a survey between July 2021 and June 2022, **** percent of adults aged 20 and 59 in the Philippines were diagnosed as obese or overweight. Obesity increases the risk for severe diseases and health conditions such as hypertension, stroke, and type 2 diabetes.

In 2021, ischaemic heart disease caused approximately ****** deaths among females in the Philippines. The other leading causes of mortality among Filipino women were neoplasms, cerebrovascular diseases, diabetes mellitus, and pneumonia.

Philippines PH: Prevalence of Overweight: Weight for Height: % of Children Under 5 data was reported at 3.900 % in 2015. This records a decrease from the previous number of 5.000 % for 2013. Philippines PH: Prevalence of Overweight: Weight for Height: % of Children Under 5 data is updated yearly, averaging 3.300 % from Dec 1992 (Median) to 2015, with 7 observations. The data reached an all-time high of 5.000 % in 2013 and a record low of 1.700 % in 1992. Philippines PH: Prevalence of Overweight: Weight for Height: % of Children Under 5 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Philippines – Table PH.World Bank: Health Statistics. Prevalence of overweight children is the percentage of children under age 5 whose weight for height is more than two standard deviations above the median for the international reference population of the corresponding age as established by the WHO's new child growth standards released in 2006.; ; UNICEF, WHO, World Bank: Joint child malnutrition estimates (JME). Aggregation is based on UNICEF, WHO, and the World Bank harmonized dataset (adjusted, comparable data) and methodology.; Linear mixed-effect model estimates; Estimates of overweight children are also from national survey data. Once considered only a high-income economy problem, overweight children have become a growing concern in developing countries. Research shows an association between childhood obesity and a high prevalence of diabetes, respiratory disease, high blood pressure, and psychosocial and orthopedic disorders (de Onis and Blössner 2003). Childhood obesity is associated with a higher chance of obesity, premature death, and disability in adulthood. In addition to increased future risks, obese children experience breathing difficulties and increased risk of fractures, hypertension, early markers of cardiovascular disease, insulin resistance, and psychological effects. Children in low- and middle-income countries are more vulnerable to inadequate nutrition before birth and in infancy and early childhood. Many of these children are exposed to high-fat, high-sugar, high-salt, calorie-dense, micronutrient-poor foods, which tend be lower in cost than more nutritious foods. These dietary patterns, in conjunction with low levels of physical activity, result in sharp increases in childhood obesity, while under-nutrition continues

Philippines PH: Prevalence of Overweight: Weight for Height: % of Children Under 5, Modeled Estimate data was reported at 3.300 % in 2024. This records a decrease from the previous number of 3.400 % for 2023. Philippines PH: Prevalence of Overweight: Weight for Height: % of Children Under 5, Modeled Estimate data is updated yearly, averaging 3.300 % from Dec 2000 (Median) to 2024, with 25 observations. The data reached an all-time high of 3.600 % in 2021 and a record low of 2.200 % in 2000. Philippines PH: Prevalence of Overweight: Weight for Height: % of Children Under 5, Modeled Estimate data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Philippines – Table PH.World Bank.WDI: Social: Health Statistics. Prevalence of overweight children is the percentage of children under age 5 whose weight for height is more than two standard deviations above the median for the international reference population of the corresponding age as established by the WHO's 2006 Child Growth Standards.;UNICEF, WHO, World Bank: Joint child Malnutrition Estimates (JME).;Weighted average;Once considered only a high-income economy problem, overweight children have become a growing concern in developing countries. Research shows an association between childhood obesity and a high prevalence of diabetes, respiratory disease, high blood pressure, and psychosocial and orthopedic disorders (de Onis and Blössner 2003). Childhood obesity is associated with a higher chance of obesity, premature death, and disability in adulthood. In addition to increased future risks, obese children experience breathing difficulties and increased risk of fractures, hypertension, early markers of cardiovascular disease, insulin resistance, and psychological effects. Children in low- and middle-income countries are more vulnerable to inadequate nutrition before birth and in infancy and early childhood. Many of these children are exposed to high-fat, high-sugar, high-salt, calorie-dense, micronutrient-poor foods, which tend be lower in cost than more nutritious foods. These dietary patterns, in conjunction with low levels of physical activity, result in sharp increases in childhood obesity, while under-nutrition continues. Estimates are modeled estimates produced by the JME. Primary data sources of the anthropometric measurements are national surveys. These surveys are administered sporadically, resulting in sparse data for many countries. Furthermore, the trend of the indicators over time is usually not a straight line and varies by country. Tracking the current level and progress of indicators helps determine if countries are on track to meet certain thresholds, such as those indicated in the SDGs. Thus the JME developed statistical models and produced the modeled estimates.